ORGANIZATION AND BUSINESS (Details) $ in Millions |
9 Months Ended |
|---|---|
|
Sep. 30, 2022
USD ($)
Facility
Product
| |
| Organization and Business [Abstract] | |
| Number of plasma collection facilities under approval and development | 10 |
| Number of FDA-licensed plasma collection facilities | 7 |
| Number of additional plasma collections centers in operation and collection of plasma | 2 |
| Number of FDA approved product | Product | 3 |
| Working capital | $ | $ 179.7 |
| Cash and cash equivalents | $ | $ 34.9 |
| X | ||||||||||
- Definition Number of additional plasma collections centers in operation and collection of plasma during the period. No definition available.
|
| X | ||||||||||
- Definition Number of products approved by FDA. No definition available.
|
| X | ||||||||||
- Definition Number of plasma collection facilities having FDA license. No definition available.
|
| X | ||||||||||
- Definition Number of plasma collection facilities under various stages of development. No definition available.
|
| X | ||||||||||
- Definition The amount of difference between current assets and liabilities. No definition available.
|
| X | ||||||||||
- Definition Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|